Updated on 27 August 2013
"The objective is to take the disease detection chip to large number of hospitals in and outside Asia. We are in process of building partnership with experienced distribution channels in the US, Europe and Asia Pacific as well as our own strong sales team," Dr Wong mentioned.
Having developed a molecular diagnostic kit, Dr Wong is now exploring relations with potential investors that will help the home-grown company to expand its R&D avenues and initiate registration processes in different geographies. Dr Wong believes in having a good relationship with the industry in order to enable a laboratory enclosed research to get adopted for large scale utilization.
Affymetrix analysed the potential of Dr Wong's genomics-based diagnostic chip and decided to partner with PathGEN Dx in 2012 for production. Having set a channel to get closer to the market, PathGEN kit is comprised of proprietary reagents, an automated software package, and a contract manufactured GeneChip microarray from Affymetrix. The product is designed to detect viral and bacterial genomes from a wide variety of human samples, annotate the genomic information and identify co-infecting pathogens.
Between 2011 and 2012, Dr Wong was granted $111,313 (S$142,582) for developing the chip that can detect protein, RNA and DNA targets simultaneously in a single chip for infectious disease diagnostics and prognostics and $184,172 (S$235,906) for validation of the chip. The next step, according to Dr Wong, is to get FDA approval for a wider adoption of the technology in a number of countries, particularly in public health laboratories, universities, hospitals and pathology labs. The company is courting venture capital (VC) firms to fund clinical trials for an anticipated FDA submission.